Injectable Bone Articles & Analysis
6 news found
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive two-year follow-up data for the Company's StemSpine® pilot study, showing significant efficacy of the StemSpine® ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, today announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine® study, showing significant efficacy of ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the Company's OvaStem® pilot study. The data shows significant efficacy of the OvaStem® ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has submitted a supplementary De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company’s antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) ...
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, has been awarded a group purchasing agreement for Synthetic Implantable Products with Premier. Effective July 1st, the new agreement allows Premier members, at their discretion, to take advantage of pricing and terms pre-negotiated by Premier for CERAMENT® BONE VOID FILLER. “The awarded ...
GRAFTYS SA (“Graftys”), a global leader in resorbable bone cements, is proud to announce that as a fruitful result of 10 years’ partnership with its distributor - LAS Brasil, the milestone of 10,000 units of GRAFTYS® HBS sold in Brazil has been crossed during the third quarter of 2020. GRAFTYS® HBS is a calcium phosphate bone graft substitute, which offers very low ...
ByGraftys